Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial
- PMID:31388599
- PMCID: PMC6667779
- DOI: 10.1016/j.conctc.2019.100412
Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial
Erratum in
- Erratum regarding missing Declaration of Competing Interest statements in previously published articles.[No authors listed][No authors listed]Contemp Clin Trials Commun. 2020 Dec 10;20:100689. doi: 10.1016/j.conctc.2020.100689. eCollection 2020 Dec.Contemp Clin Trials Commun. 2020.PMID:33392413Free PMC article.
Abstract
Tobacco smoking is a global pandemic that poses substantial health burdens and costs. With nearly six million deaths annually, smoking is the single most important cause of avoidable premature mortality in the world, mainly from lung cancer, coronary heart disease, chronic obstructive pulmonary disease and stroke. Smoking is a very difficult addiction to break, even for those with a strong desire to quit. Electronic cigarettes are an attractive long-term alternative source of nicotine to conventional cigarettes because of their many similarities with smoking. Electronic cigarette users report buying them to reduce cigarette consumption, to relieve tobacco withdrawal symptoms, to quit, and to continue having a 'smoking' experience, but with reduced health risks. Actually, there aren't antismoking treatments for people who smoke only electronic cigarette (single users) or electronic cigarette and classic cigarette (dual users). There isn't any specific information on the efficacy and safety of new pharmacological support for electronic cigarette users. We propose that smoking cessation with varenicline plus counselling delivered to electronic cigarette users could be associated with similar smoking abstinence rates compared to the results obtained in the general population. Herein, we describe the methodology of a double-blind, placebo-controlled, randomized clinical trial, of 24 weeks duration, that examines the efficacy of varenicline (1 mg BID - for 12 weeks) plus counselling compared to matched placebo (1 mg BID - for 12 weeks) plus counselling.
Keywords: Electronic cigarettes; Randomised controlled trial; Smoking; Varenicline.
Similar articles
- Varenicline for smoking cessation in individuals who smoke cigarettes and use electronic cigarettes: a double-blind, randomised, placebo-controlled phase 3 trial.Caponnetto P, Spicuzza L, Campagna D, Ahluwalia JS, Russell C, Maglia M, Riela PM, Longo CF, Caci G, Quattropani MC, Signorelli MS, Polosa R.Caponnetto P, et al.EClinicalMedicine. 2023 Nov 21;66:102316. doi: 10.1016/j.eclinm.2023.102316. eCollection 2023 Dec.EClinicalMedicine. 2023.PMID:38192585Free PMC article.
- Randomised, placebo-controlled, double-blind, double-dummy, multicentre trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine: the ECSMOKE trial protocol.Berlin I, Dautzenberg B, Lehmann B, Palmyre J, Liégey E, De Rycke Y, Tubach F.Berlin I, et al.BMJ Open. 2019 May 24;9(5):e028832. doi: 10.1136/bmjopen-2018-028832.BMJ Open. 2019.PMID:31129603Free PMC article.Clinical Trial.
- Nicotine receptor partial agonists for smoking cessation.Cahill K, Stead LF, Lancaster T.Cahill K, et al.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6.Cochrane Database Syst Rev. 2012.Update in:Cochrane Database Syst Rev. 2016 May 09;(5):CD006103. doi: 10.1002/14651858.CD006103.pub7.PMID:22513936Updated.Review.
- Vaping characteristics and expectancies are associated with smoking cessation propensity among dual users of combustible and electronic cigarettes.Brandon KO, Simmons VN, Meltzer LR, Drobes DJ, Martínez Ú, Sutton SK, Palmer AM, Bullen CR, Harrell PT, Brandon TH.Brandon KO, et al.Addiction. 2019 May;114(5):896-906. doi: 10.1111/add.14551. Epub 2019 Feb 13.Addiction. 2019.PMID:30644627Free PMC article.Clinical Trial.
- Nicotine receptor partial agonists for smoking cessation.Cahill K, Stead LF, Lancaster T.Cahill K, et al.Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5.Cochrane Database Syst Rev. 2011.Update in:Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6.PMID:21328282Updated.Review.
Cited by
- Electronic cigarettes for smoking cessation.Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Butler AR, Hajek P.Hartmann-Boyce J, et al.Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD010216. doi: 10.1002/14651858.CD010216.pub4.Cochrane Database Syst Rev. 2020.Update in:Cochrane Database Syst Rev. 2021 Apr 29;4:CD010216. doi: 10.1002/14651858.CD010216.pub5.PMID:33052602Free PMC article.Updated.
- Electronic cigarettes for smoking cessation.Hartmann-Boyce J, McRobbie H, Butler AR, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Fanshawe TR, Hajek P.Hartmann-Boyce J, et al.Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub6.Cochrane Database Syst Rev. 2021.Update in:Cochrane Database Syst Rev. 2022 Nov 17;11:CD010216. doi: 10.1002/14651858.CD010216.pub7.PMID:34519354Free PMC article.Updated.Review.
- Interventions for preventing weight gain after smoking cessation.Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P.Hartmann-Boyce J, et al.Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4.Cochrane Database Syst Rev. 2021.PMID:34611902Free PMC article.Review.
- Nicotine receptor partial agonists for smoking cessation.Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N.Livingstone-Banks J, et al.Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.Cochrane Database Syst Rev. 2023.PMID:37142273Free PMC article.Review.
- Effect of unguided e-cigarette provision on uptake, use, and smoking cessation among adults who smoke in the USA: a naturalistic, randomised, controlled clinical trial.Carpenter MJ, Wahlquist AE, Dahne J, Gray KM, Cummings KM, Warren G, Wagener TL, Goniewicz ML, Smith TT.Carpenter MJ, et al.EClinicalMedicine. 2023 Aug 15;63:102142. doi: 10.1016/j.eclinm.2023.102142. eCollection 2023 Sep.EClinicalMedicine. 2023.PMID:37753443Free PMC article.
References
- Bartecchi C.E., MacKenzie T.D., Schrier R.W. The human cost of tobacco use. N. Engl. J. Med. 1994;330:907–912. - PubMed
- World Health Organization (WHO . WHO Press; Geneva: 2003. WHO Framework Convention on Tobacco Control.
- Fiore M., Jaén C., Baker T., Benowitz N., Curry S., Dorfman S. Clinical Practice Guideline, Department of Health and Human Services, Public Health Service; Rockville, MD: May 2008. Treating Tobacco Use and Dependence: 2008 Update. U.S.
- Caponnetto P., Russo C., Bruno C.M., Alamo A., Amaradio M.D., Polosa R. Electronic cigarette: a possible substitute for cigarette dependence. Monaldi Arch. Chest Dis. 2013;79:12–19. - PubMed
- Jorenby D.E., Hays J.T., Rigotti N.A. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J. Am. Med. Assoc. 2006;296:56–63. - PubMed
Related information
LinkOut - more resources
Full Text Sources